Natera (NTRA) Director Jonathan Sheena Sells $604K of Stock

Natera, Inc. director Jonathan Sheena sold 1,500 shares of the diagnostics company on October 16, 2026. The transaction was filed with the Securities and Exchange Commission on a Form 4. Natera shares closed at $393.44 on the day of the sale.

NTRA Natera, Inc.

$400.55 ▲ +75.03% year to date

1M 3M YTD

Daily close · Oct 20, 2026

Inside Jonathan Sheena's NTRA Trade

Sheena executed the sale at an average price of $402.47 per share, bringing the total value of the transaction to $603,710.25. The trade was carried out under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, Sheena holds 8,250 shares of the company, representing a 15.38% reduction in his direct stake.

Other Institutional Activity in Natera

Duquesne Family Office Llc grew its holdings by 122,845 shares, ending with 3,186,306 shares worth about $1.29 billion as of June 30, 2026.

Natera, Inc. Stock Up 2.5%

Natera shares recently traded around $409.55 as of October 21, 2026, putting the stock up about 4.1% since the transaction date. The stock trades well above its 50-day moving average of $361.38 and its 200-day moving average of $259.23, while sitting below its 52-week high of $437.41. The company carries a market capitalization of roughly $58.51 billion.

Recent Earnings

Natera reported trailing-twelve-month revenue of $2.71 billion with an EPS of -$1.35. The company's next earnings report is scheduled for November 5, 2026.

Insider Buying and Selling at Natera, Inc.

Earlier insider activity at Natera includes a sale by Executive Chairman Matthew Rabinowitz, who sold 50,000 shares for roughly $20.1 million on October 15, 2026, under a planned trading program. Prior open-market transactions in June 2026 included smaller share acquisitions by Rowan Chapman, Lynch Thomas JR., and Roelof Botha.

Analysts Set New Price Targets

Wall Street firms have updated their outlooks on Natera ahead of upcoming financial reports. Citigroup maintained a Buy rating on October 6, 2026, lifting its target to $480. Barclays reiterated an Overweight rating with a $475 target on October 7, 2026. Morgan Stanley maintained its Overweight rating with a $435 target on October 13, 2026, while TD Cowen kept a Buy rating and a $480 target the same day. JP Morgan maintained an Overweight rating with a $460 target on October 14, 2026. Later, Canaccord Genuity maintained a Buy rating and raised its target to $500 on October 19, 2026. The stock holds a consensus Strong Buy rating with a mean price target of $409.57 across 22 analyst opinions.

About Natera

Natera, Inc. provides molecular testing and diagnostic services. The Austin, Texas-based company focuses on personalized cell-free DNA testing for oncology, women's health, and organ health monitoring, helping clinicians track cancer recurrence and guide treatment decisions.

Bottom Line

Investors are tracking insider transactions alongside institutional moves as Natera approaches its next financial results release on November 5, 2026. Form 4 filings provide transparency into executive and director trading plans over time.